Skip to main content

Erytech Pharma S.A. (ERYP)

NASDAQ: ERYP · IEX Real-Time Price · USD
5.88 -0.17 (-2.81%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap163.77M
Revenue (ttm)4.93M
Net Income (ttm)-78.92M
Shares Out27.73M
EPS (ttm)-3.72
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume10,315
Open6.07
Previous Close6.05
Day's Range5.88 - 6.05
52-Week Range4.10 - 13.00
Beta1.92
AnalystsStrong Buy
Price Target17.76 (+202.0%)
Est. Earnings Daten/a

About ERYP

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-l...

IndustryBiotechnology
Founded2004
CEOGil Beyen
Employees196
Stock ExchangeNASDAQ
Ticker SymbolERYP
Full Company Profile

Financial Performance

In 2020, Erytech Pharma's revenue was 3.72 million, a decrease of -29.62% compared to the previous year's 5.28 million. Losses were -73.30 million, 17.0% more than in 2019.

Financial numbers in millions EURFinancial Statements

Analyst Forecast

According to 3 analysts, the average rating for Erytech Pharma stock is "Strong Buy." The 12-month stock price forecast is 17.76, which is an increase of 202.05% from the latest price.

Price Target
$17.76
(202.05% upside)
Analyst Consensus: Strong Buy

News

ERYTECH Announces the Availability of its Half-Year Financial Report 2021

ERYTECH Announces the A vailability of its H alf- Y ear F inancial R eport 202 1

2 days ago - GlobeNewsWire

ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2021

ERYTECH Provides Business Update and Reports Financial Results for the First Half of 20 2 1

4 days ago - GlobeNewsWire

ERYTECH to Host on September 21, 2021 Second Quarter 2021 conference call and Business Update

ERYTECH t o Host on September 21, 2021 Second Quarter 2021 conference call and Business Update

1 week ago - GlobeNewsWire

ERYTECH to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Cambridge, MA (U.S.) and Lyon (France), September 6, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeu...

2 weeks ago - GlobeNewsWire

ERYTECH to Participate in the Citi 16th Annual BioPharma Conference

ERYTECH to Participate in the Citi 16 th Annual BioPharma Conference

3 weeks ago - GlobeNewsWire

ERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer

ERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer

1 month ago - GlobeNewsWire

ERYP Stock: The Huge FDA News That Has Little-Known Erytech Skyrocketing

ERYP stock is seeing a surge in value this morning, as it lands FDA fast track designation for its eryaspase treatment for a second time. The post ERYP Stock: The Huge FDA News That Has Little-Known Ery...

1 month ago - InvestorPlace

Why Erytech Pharma's Stock Is Surging Higher Today

Erytech Pharma SA (NASDAQ: ERYP) is surging higher Friday morning after the company announced its eryaspase was granted U.S. FDA Fast Track designation. The Fast Track designation is for the treatment o...

1 month ago - Benzinga

Why Erytech Pharma Shares Are Soaring Today

Erytech Pharma SA (NASDAQ: ERYP) is surging higher in after hours trading after the company announced its eryaspase was granted U.S. FDA Fast Track designation. The Fast Track designation is for the tre...

1 month ago - Benzinga

ERYTECH Granted U.S. FDA Fast Track Designation for Eryaspase in Hypersensitive ALL

ERYTECH Granted U.S. FDA Fast Track Designation  for E ryaspase in Hypersensitive ALL

1 month ago - GlobeNewsWire

ERYTECH to Participate in the BTIG Virtual Biotechnology Conference

ERYTECH to Participate in the BTIG Virtual Biotechnology Conference

1 month ago - GlobeNewsWire

ERYTECH Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Patients

ERYTECH Confirms Plans To Submit BLA for E ryaspase in H ypersensitive ALL Patients

2 months ago - GlobeNewsWire

Report - Erytech's Combined Shareholders' Meeting on June 25, 2021

REPORT - ERYTECH'S COMBINED SHAREHOLDERS' MEETING ON JUNE 25, 2021

2 months ago - GlobeNewsWire

ERYTECH to Participate in Upcoming Virtual Investor Conferences in June

ERYTECH to Participate in Upcoming Virtual Investor Conferences in June

3 months ago - GlobeNewsWire

Erytech's Combined Shareholders' Meeting on June 25, 2021

ERYTECH'S COMBINED SHAREHOLDERS' MEE TING

3 months ago - GlobeNewsWire

ERYTECH Provides Business Update and Reports Financial Results for the First Quarter of 2021

ERYTECH Provides Business Update and Reports Financial Results for the First Quarter of 20 2 1

4 months ago - GlobeNewsWire

ERYTECH Announces $30.0 Million Registered Direct Offering

ERYTECH Announces $ 30.0 Million Registered Direct Offering

4 months ago - GlobeNewsWire

ERYTECH Reports Cash Balance at End of Q1 2021 and Announces the Details of its 2021 Q1 conference call

ERYTECH Reports Cash Balance at End of Q1 202 1 and Announces the Details of its 2021 Q1 conference call

4 months ago - GlobeNewsWire

ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL

ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL

5 months ago - GlobeNewsWire

ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pan...

ERYTECH Announces Completion of First Cohort i n a Phase 1 Investigator Sponsored Trial of Eryaspase in First -Line Pancreatic Cancer

5 months ago - GlobeNewsWire

ERYTECH to Participate in Upcoming Virtual Investor Conferences in April

ERYTECH to Participate in Upcoming Virtual Investor Conferences in April

5 months ago - GlobeNewsWire

ERYTECH Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F

ERYTECH Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F

6 months ago - GlobeNewsWire

ERYTECH Pharma (ERYP) Sees Hammer Chart Pattern: Time to Buy?

ERYTECH Pharma S.A. (ERYP) has been struggling lately, but the selling pressure may be coming to an end soon

6 months ago - Zacks Investment Research

ERYTECH to Present at the 2021 BIO CEO & Investor Conference

ERYTECH to Present at the 2021 BIO CEO & Investor Conference

7 months ago - GlobeNewsWire

ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancrea...

ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

8 months ago - GlobeNewsWire